Your COVID-19 questions answered

We assembled our experts to offer responses to some of the most pressing questions regarding the current state of the pandemic. From the startling emergence of the Omicron variant to the use of rapid antigen tests to the recommendation and timing of third dose booster vaccines. The evidence collected by CITF-funded research so far has helped to inform health care and public health decisions with regard to the ever-changing situation. We hope that it will help you to make informed choices regarding your health and to stay safe.

If a child has had a SARS-CoV-2 infection, regardless of the variant, the National Advisory Committee on Immunization (NACI) recommends that they still receive two doses of vaccine at the recommended eight-week interval, if currently eligible, and once symptoms have resolved and the child is no longer considered infectious (NACI). For specific recommendations, contact your healthcare provider.

If a child has recovered from an infection with SARS-CoV-2, including with the Omicron variant, between their first and second dose, they should still receive their second dose, as recommended by NACI. Since the extent of protection from infection versus vaccination in children is unknown, all eligible children should be vaccinated with the two-dose COVID-19 vaccine regimen. Although infection builds immunity, vaccination provides more robust protection. Importantly, provinces and territories have their own set of recommendations for the timing of vaccines after an infection, so it is highly recommended to verify with local public health units.

It is highly recommended that adults get a third (booster) dose, even after an infection with Omicron. It should ideally not be delayed more than three to six months after infection, as SARS-CoV-2-specific antibodies wane naturally over time1-3, potentially leaving a person vulnerable to reinfection. Receiving a third (booster) dose immediately after recovery from an infection with Omicron is not harmful, but waiting two to three months after symptoms have resolved will help optimize and refine the immune response and immune memory. This also applies to individuals who have contracted SARS-CoV-2 between their first and second dose of vaccine. Importantly, provinces and territories have their own set of recommendations for the timing of vaccines after an infection, so it is highly recommended to verify with local public health units.

Vaccination is one of the best tools to limit severe disease. Being optimally protected includes receiving a third dose – even for those previously infected – while continuing to follow local public health measures. For specific recommendations, contact your healthcare provider.

At-home rapid antigen tests for COVID-19 have become more commonplace in the absence of widespread PCR testing. They are called antigen tests because they detect antigens, specific proteins that make-up the SARS-CoV-2 virus. Further, they provide test results in less than an hour, hence the designation ‘rapid’.

A rapid antigen test’s sensitivity, defined as its ability to detect the virus when present, is dependent on an individual’s viral load. Viral loads – the amount of virus in nasopharyngeal fluids and blood – are higher early on in infection when the virus is replicating exponentially4. Viral loads are generally detectable for some rapid antigen tests during the first five days of symptoms (Health Canada). After this initial period, rapid antigen test performance decreases quickly as viral loads decline, and the infection clears.

Rapid antigen tests detect current infections, including those caused by Omicron5. They cannot, however, tell whether an individual has had a previous infection with SARS-CoV-2. Vaccination against COVID-19 does not interfere with the test’s ability to detect a current infection.

Figure 1: Schematic depiction of the COVID-19 rapid antigen tests available in Canada.

Step 1 – Specimen collection.

A nasal sample is collected using the sterile swab provided. Blowing the nose prior to swabbing, tilting the head back 70 degrees, compressing the nostril with the aid of fingers, and using circular motions while in the nasal cavity have been known to aid with collection.

Step 2 – Test procedure.

The swab is submerged in a buffer solution to extract the SARS-CoV-2 virus (if present). After a rest period, the resulting liquid is dispensed with the aid of a nozzle into the sample well on the testing device. The sample then moves through the testing device during which antigens present in the sample bind to antibodies in the device, forming antigen-antibody complexes. The reaction lasts for 15-30 minutes (depending on the manufacturer’s instructions) after which results may be read.

Step 3 – Results interpretation.

Two lines detected at the T (test) and C (control) lines of the test window indicate a positive result. This means the sample is positive for SARS-CoV-2 and the person is most likely infected. Positive results can be reported at local/provincial/territorial Public Health units or at independent initiatives such as The Rapid Test Tracker. If only one line at C (control) appears, the result is negative, meaning that the individual is most likely not infected. *It is important to note however that a negative result may also indicate that a person is infected but below the level of detection. That said, if symptoms are present, individuals should continue to isolate and follow local public health guidelines. The test may be repeated a few days later to re-ascertain infection status. No lines or a faint T line indicates an invalid test. A test cannot be used more than once.

Some of the rapid antigen tests that have received Health Canada approval for diagnostic testing are shown below, and additional information can be found here.

Table 1: Specifications of some of the rapid antigen tests available in Canada.

  Country of manufacture Sensitivity* Specificity** Overall agreement*** Limit of detection
BTNX – Rapid Response COVID-19 Antigen Test Canada 95.5% 95.5% 97.3% 2×102.4 TCID50/mL
Artron Antigen COVID-19 (SARS-CoV-2) Rapid Test Canada 97.2% 99.6% 97.0% 1×103


Quidel Quickvue At-home OTC COVID-19 Test USA 83.5% 99.2% 90.0% 1.9×104


BD Veritor System for Rapid Detection of SARS-CoV-2 USA 84% 100.0% 96.0% 800 genomic RNA copies/ml
Roche Rapid Antigen Test Germany 82.2% 99.0% 95.0% 9.25×101.2 TCID50/mL
Abbott – Panbio COVID-19 Antigen Rapid Test Germany 75.5% 94.9% 90.0% Viral loads > 106 copies/ml
Xiamen Boson Biotech – SARS-CoV-2 Antigen Test Card China 96.5% 99.0% 98.7% 130


Empowered Diagnostics CovClear COVID-19 Rapid Antigen Test USA 95.5% 100.0% 96.7% 1.29×105 TCID50/ml

* Sensitivity is a metric defining a test’s capacity to correctly identify people that are infected with SARS-CoV-2 when a test is positive. For example, a test with a sensitivity of 96% will, on average, correctly identify 96 people in every 100 who are truly infected with SARS-CoV-2.

** Specificity is a metric defining a test’s capacity to correctly identify people that are not infected with SARS-CoV-2 when a test is negative. For example, a test with a specificity of 96% will, on average, correctly identify 96 people in every 100 who are truly not infected with SARS-CoV-2.

*** Overall agreement: is the product of the equation: true positives + true negatives / total samples.

Experts are still analyzing data to understand the extent of the severity of disease and potential long-term implications from infection with the Omicron variant. This includes characterizing disease severity in infected individuals vaccinated with one, two, three, or four doses compared to those not yet vaccinated. Currently, population-level disease appears less severe with Omicron compared to Delta (Public Health Ontario). Reports worldwide have described infection with Omicron to be mild to moderate in most cases6-8. Nevertheless, people who are older, with underlying health conditions, or are immunosuppressed may have a higher risk of more severe disease, including life-threatening illness9, 10. Likewise, the impact on healthcare systems will be significant due to the sheer number of cases and increased transmissibility of the new variant.

Symptoms from an infection with Omicron are like those previously reported for COVID-19: fever, cough, sore throat, tiredness, and headache being the most common.  Individuals with COVID-19-like symptoms should self-isolate.

Yes, the Omicron variant has been associated with an increased risk of reinfection, that is, new infections with SARS-CoV-2 in previously recovered individuals. This is due to the substantial number of new genetic mutations found in Omicron compared to previous strains, including the Delta variant that was widely circulating in the third and fourth viral waves. Reports show a series of at least 36 mutations in the virus’ spike protein, about half being in the receptor-binding domain (RBD), compared to the original strain of the virus (11). These have been linked to increased transmissibility and immune evasion, meaning that the antibodies made from previous infection or vaccination don’t recognize Omicron (12-15). Since the new variant ‘looks’ very different, antibodies may not be able to respond to it.


  1. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372-7.
  2. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
  3. Zhang A, Breznik JA, Clare R, Nazy I, Miller MS, Bowdish DME, et al. Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents. J Am Med Dir Assoc. 2022.
  4. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.
  5. Bekliz M, Perez-Rodriguez F, Puhach O, Adea K, Melancia SM, Baggio S, et al. Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. medRxiv. 2022:2021.12.18.21268018.
  6. Sheikh A KS, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. 2021 Dec 22.
  7. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022.
  8. Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. N Engl J Med. 2021;385(26):2487-9.